

Recommendations of the SEC (Ophthalmology) made in its 01st/26 meeting held on 20.01.2026 at CDSCO HQ New Delhi:

S. No	File Name & Drug Name, Strength	Firm Name	Recommendations
SND Division			
1.	SND/MA/25/000223 Sodium Hyaluronate Eye Drops 0.3 % w/v	M/s. Ajanta Pharma limited	<p>The firm intends to present Phase III CT protocol of Sodium Hyaluronate Eye Drops 0.3 % w/v before the committee. During presentation by the firm, one of the experts have raised concern that the applied product (Sodium Hyaluronate Eye Drops 0.3 % w/v, Brand name: Maxmoist Ultra Eye Drops & Softvisc Ultra Lubricant Eye Drops of Ajanta Pharma Limited) is reflected to be available in the online platform.</p> <p>The firm was asked to clarify from their marketing team regarding availability of applied product in the market. The firm sought the time to submit clarification to CDSCO. Hence, the deliberation of Phase III CT protocol of Sodium Hyaluronate Eye Drops 0.3 % w/v was not made and proposal was deferred.</p>